Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13702420 | 0.85 | VNN1 (0.44) | VNN1S1PR3S1PR1S1PR4GRM4 | |
| SCHEMBL22231515 | 0.83 | CA12 (0.54) | CA12CA1CA2CA9CA14 | |
| SCHEMBL31366876 | 0.83 | CA12 (0.54) | CA12CA1CA2CA9CA14 | |
| SCHEMBL926113 | 0.82 | VNN1 (0.45) | VNN1S1PR3NAMPTS1PR1S1PR4 | |
| SCHEMBL19771775 | 0.82 | VNN1 (0.42) | VNN1S1PR3NAMPTS1PR1S1PR4 | |
| SCHEMBL22231457 | 0.81 | CA12 (0.51) | CA12CA1CA2CA9CA14 | |
| SCHEMBL3612508 | 0.80 | VNN1 (0.47) | VNN1S1PR3S1PR1S1PR4GRM4 | |
| SCHEMBL3821201 | 0.80 | S1PR3 (0.47) | VNN1S1PR3S1PR1S1PR4GRM4 | |
| SCHEMBL22231390 | 0.79 | MAOA (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL26799630 | 0.78 | HDAC1 (0.61) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232620-A1 | 3-Aminoindazoles | SGK3, SGK1, SGK2 | CA12 4882/4885CA1 4881/4885CA2 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.